Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status

Immune checkpoint blockade therapy targeting programmed death (PD)-1 or PD-ligand1 (L1) has shown promising results in renal cell carcinoma (RCC); however, the prognostic implications and clinicopathological features of PD-L1 and PD-L2 expression in RCC remain unclear.

PD-L1 and PD-L2 expression was immunohistochemically evaluated in 425 resected RCCs of variable histologic subtypes and analyzed according to the clinicopathological status and oncogenic proteins status.

PD-L1 expression was observed in 9. 4 % with no difference between histologic subtypes, but PD-L2 was observed in 49. 6 % with highest frequency in papillary RCC (PRCC) (P < 0. 001). In clear cell RCC (CCRCC), PD-L1 expression was associated with adverse features, including higher nuclear grade, necrosis, sarcomatoid transformation, c-MET expression (all, P < 0. 001) and VEGF expression (P = 0. 002), whereas PD-L2 expression was related with c-MET and VEGF expression (P = 0. 008 and P < 0. 001). In PRCC, positive correlations between PD-L1 and EGFR expression (P = 0. 007) or between PD-L2 and VEGF expression (P < 0. 001) were observed. In CCRCC, PD-L1 and PD-L2 positivity were significantly associated with shorter progression-free survival (P < 0. 001; P = 0. 033) and cancer-specific survival (P < 0. 001; P = 0. 010), but not in PRCC.

PD-L1 and PD-L2 expression predict poor prognosis in CCRCC. Thus, PD-1/PD-L pathway-targeted immunotherapy may be useful for treatment of patients with CCRCC.

Annals of surgical oncology. 2015 Oct 13 [Epub ahead of print]

Su-Jin Shin, Yoon Kyung Jeon, Pil-Jong Kim, Yong Mee Cho, Jaemoon Koh, Doo Hyun Chung, Heounjeong Go

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. , Department of Pathology, Seoul National University Hospital, Seoul, Korea. , Biomedical Knowledge Engineering Laboratory, School of Dentistry, Seoul National University, Seoul, Korea. , Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. , Department of Pathology, Seoul National University Hospital, Seoul, Korea. , Department of Pathology, Seoul National University Hospital, Seoul, Korea. , Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 

PubMed